Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingfeijieduhuatan
- Development stage
- Unknown
- Lead developer
- Henan University of Chinese Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Qingfeijieduhuatan is a Traditional Chinese Medicine (TCM) granule formulation developed for the treatment of severe community-acquired pneumonia (CAP). It is specifically indicated for patients presenting with the 'phlegm-heat obstructing in the lung' syndrome. The drug is being evaluated in Phase 3 clinical trials by the Henan University of Traditional Chinese Medicine as part of an integrated medicine approach, where it is administered alongside conventional Western antibiotic therapy. Manufactured by Sanjiu Medical & Pharmaceutical Co., Ltd., the formulation is designed to clear pulmonary heat, neutralize toxins, and facilitate the resolution of phlegm to improve clinical outcomes in critically ill pneumonia patients.
- Other names
- Qingfeijieduhuatan granule
Beyond the preview
Go deeper on Qingfeijieduhuatan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qingfeijieduhuatan.